Dentsply North America Explodes from within

Don must go. He is the worst thing that happened to this company.

 

actually, our board of directors is our problem. However, like Jussie Smollett, they aren’t responsible for anything.

 

Our stock would say otherwise

 

I heard mike godfrey said people were let go at tulsa lay-off call and then asked anyone still there if they wanted a cookie....Hope the chocolate chip went down well douche nozzle

 

Is stock price the only measurement of the health of a company? I think not.

 

Dear York employees, I see they are relocating the headquarters to Charlotte and that they say your jobs are safe.

We heard the same thing in Tulsa.

Good luck.

 

The CFO relocated to York, but won’t relocate to Charlotte.
Let be be the first to call complete bullshit on that.

 

So is there an expansion here? Many openings for District managers?

 

https://rocklandregister.com/2019/06/05/insider-selling-dentsply-sirona-inc-xray-svp-sells-54402-shares-of-stock.html

DENTSPLY SIRONA Inc (NASDAQ:XRAY) SVP Sells $2,992,110.00 in Stock
Posted by Kim Weber on Jun 5th, 2019 // Comments off

DENTSPLY SIRONA Inc (NASDAQ:XRAY) SVP Maureen J. Macinnis sold 54,402 shares of DENTSPLY SIRONA stock in a transaction dated Thursday, May 9th. The shares were sold at an average price of $55.00, for a total value of $2,992,110.00. Following the completion of the transaction, the senior vice president now owns 50,962 shares of the company’s stock, valued at approximately $2,802,910. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Shares of DENTSPLY SIRONA stock opened at $54.40 on Wednesday. DENTSPLY SIRONA Inc has a twelve month low of $33.93 and a twelve month high of $55.88. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.35 and a current ratio of 2.06. The company has a market cap of $12.60 billion, a PE ratio of 27.06, a P/E/G ratio of 2.01 and a beta of 0.95.

Get DENTSPLY SIRONA alerts:

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Friday, May 3rd. The medical instruments supplier reported $0.49 EPS for the quarter, beating the consensus estimate of $0.39 by $0.10. DENTSPLY SIRONA had a positive return on equity of 8.99% and a negative net margin of 26.48%. The firm had revenue of $946.20 million for the quarter, compared to analysts’ expectations of $925.13 million. During the same period last year, the firm earned $0.45 EPS. The firm’s revenue was down 1.0% compared to the same quarter last year. As a group, research analysts expect that DENTSPLY SIRONA Inc will post 2.34 EPS for the current year.



The company also recently declared a quarterly dividend, which will be paid on Friday, July 12th. Shareholders of record on Friday, June 28th will be paid a dividend of $0.0875 per share. This is a positive change from DENTSPLY SIRONA’s previous quarterly dividend of $0.09. This represents a $0.35 dividend on an annualized basis and a yield of 0.64%. The ex-dividend date is Thursday, June 27th. DENTSPLY SIRONA’s dividend payout ratio (DPR) is presently 17.41%.


A number of research firms have commented on XRAY. Zacks Investment Researchupgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $61.00 target price on the stock in a research report on Saturday, May 11th. BidaskClub downgraded DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a research report on Friday, May 24th. Wolfe Research initiated coverage on DENTSPLY SIRONA in a research report on Thursday, May 30th. They issued a “peer perform” rating for the company. UBS Group upped their target price on DENTSPLY SIRONA from $42.00 to $53.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 12th. Finally, Guggenheim initiated coverage on DENTSPLY SIRONA in a report on Wednesday, April 17th. They issued a “neutral” rating and a $54.00 price target for the company. Nine research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $53.62.

A number of hedge funds and other institutional investors have recently modified their holdings of XRAY. BlackRock Inc. boosted its stake in shares of DENTSPLY SIRONA by 1.8% during the 4th quarter. BlackRock Inc. now owns 14,334,332 shares of the medical instruments supplier’s stock worth $533,380,000 after acquiring an additional 257,243 shares in the last quarter. Veritas Asset Management LLP boosted its stake in shares of DENTSPLY SIRONA by 0.6% during the 1st quarter. Veritas Asset Management LLP now owns 13,549,320 shares of the medical instruments supplier’s stock worth $671,911,000 after acquiring an additional 76,545 shares in the last quarter. Mackenzie Financial Corp boosted its stake in shares of DENTSPLY SIRONA by 17.3% during the 4th quarter. Mackenzie Financial Corp now owns 10,090,056 shares of the medical instruments supplier’s stock worth $375,451,000 after acquiring an additional 1,490,134 shares in the last quarter. Select Equity Group L.P. boosted its position in shares of DENTSPLY SIRONA by 74.8% in the first quarter. Select Equity Group L.P. now owns 8,590,126 shares of the medical instruments supplier’s stock worth $425,984,000 after buying an additional 3,675,857 shares during the period. Finally, Morgan Stanley boosted its position in shares of DENTSPLY SIRONA by 1,233.9% in the third quarter. Morgan Stanley now owns 5,242,702 shares of the medical instruments supplier’s stock worth $197,860,000 after buying an additional 4,849,652 shares during the period. 91.67% of the stock is owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

 

CHRO sells $3m in stock and then DS sends employees communication about the Employee Stock Purchase Plan Open Enrollment the next day.

York HQ is moving to Charlotte.

What isn't going on these days at DS?

 

What’s not going on? Wage increases, cost of living adjustments, anything that helps the average everyday employee, forethought

 

https://techknowbits.com/2019/06/18/neuberger-berman-group-llc-sells-604378-shares-of-dentsply-sirona-inc-nasdaqxray.html

Maureen J. Macinnis Sells 15,000 Shares of DENTSPLY SIRONA Inc (NASDAQ:XRAY) Stock
Posted by Cindy Kellogue on Jun 13th, 2019

DENTSPLY SIRONA Inc (NASDAQ:XRAY) SVP Maureen J. Macinnis sold 15,000 shares of DENTSPLY SIRONA stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $56.06, for a total transaction of $840,900.00. Following the completion of the sale, the senior vice president now directly owns 25,360 shares of the company’s stock, valued at approximately $1,421,681.60. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

XRAY opened at $56.90 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.35 and a current ratio of 2.06. DENTSPLY SIRONA Inc has a fifty-two week low of $33.93 and a fifty-two week high of $57.71. The firm has a market cap of $13.31 billion, a P/E ratio of 28.31, a PEG ratio of 2.08 and a beta of 0.95.

Get DENTSPLY SIRONA alerts:

DENTSPLY SIRONA (NASDAQ:XRAY) last released its earnings results on Friday, May 3rd. The medical instruments supplier reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.10. DENTSPLY SIRONA had a negative net margin of 26.48% and a positive return on equity of 8.99%. The company had revenue of $946.20 million for the quarter, compared to analysts’ expectations of $925.13 million. During the same quarter in the previous year, the company earned $0.45 EPS. DENTSPLY SIRONA’s revenue for the quarter was down 1.0% on a year-over-year basis. As a group, equities analysts expect that DENTSPLY SIRONA Inc will post 2.35 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 12th. Investors of record on Friday, June 28th will be paid a dividend of $0.0875 per share. This is a boost from DENTSPLY SIRONA’s previous quarterly dividend of $0.09. The ex-dividend date is Thursday, June 27th. This represents a $0.35 dividend on an annualized basis and a dividend yield of 0.62%. DENTSPLY SIRONA’s payout ratio is 17.41%.

XRAY has been the topic of several analyst reports. Zacks Investment Research upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $55.00 price target on the stock in a research note on Saturday, March 9th. Bank of America initiated coverage on shares of DENTSPLY SIRONA in a research note on Monday, March 18th. They set a “buy” rating and a $57.00 price target on the stock. BidaskClub cut shares of DENTSPLY SIRONA from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 23rd. ValuEngine upgraded shares of DENTSPLY SIRONA from a “hold” rating to a “buy” rating in a research note on Saturday, May 4th. Finally, HC Wainwright set a $49.00 price target on shares of DENTSPLY SIRONA and gave the stock a “hold” rating in a research note on Friday, April 5th. Eight analysts have rated the stock with a hold rating and eight have given a buy rating to the company. DENTSPLY SIRONA has an average rating of “Buy” and a consensus target price of $53.62.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Nomura Asset Management Co. Ltd. lifted its stake in shares of DENTSPLY SIRONA by 0.7% during the 4th quarter. Nomura Asset Management Co. Ltd. now owns 39,575 shares of the medical instruments supplier’s stock valued at $1,473,000 after buying an additional 268 shares in the last quarter. Advisor Partners LLC lifted its stake in DENTSPLY SIRONA by 3.1% in the 1st quarter. Advisor Partners LLC now owns 10,169 shares of the medical instruments supplier’s stock worth $504,000 after purchasing an additional 304 shares in the last quarter. Biltmore Family Office LLC lifted its stake in DENTSPLY SIRONA by 5.8% in the 1st quarter. Biltmore Family Office LLC now owns 5,715 shares of the medical instruments supplier’s stock worth $284,000 after purchasing an additional 315 shares in the last quarter. Utah Retirement Systems lifted its stake in DENTSPLY SIRONA by 0.9% in the 1st quarter. Utah Retirement Systems now owns 41,160 shares of the medical instruments supplier’s stock worth $2,041,000 after purchasing an additional 367 shares in the last quarter. Finally, Mason Street Advisors LLC lifted its stake in DENTSPLY SIRONA by 1.2% in the 1st quarter. Mason Street Advisors LLC now owns 31,749 shares of the medical instruments supplier’s stock worth $1,574,000 after purchasing an additional 373 shares in the last quarter. Institutional investors own 91.68% of the company’s stock.

DENTSPLY SIRONA Company Profile

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

 

Obviously well deserved, based on our slew of HR problems.

 

Obviously well deserved, based on our never ending slew of HR problems.

 

MM is gone now

 

When did MM leave and where has she gone?

 

How is Clinical Development Manager division, Spear, E-Commerce and Dentsply Sirona Rewards going?

 

The C in C-suite stands for Clowns.

 

Ok r*****.